AstraZeneca on Wednesday said that its experimental drug anselamimab did not meet the main goal of a late-stage study for the treatment of AL amyloidosis, a rare condition that causes a buildup of ...

With the company's market capitalization at Rs 2,292.62 Crore, this dividend payout reflects AstraZeneca's commitment to returning value to its shareholders.

(Reuters) -AstraZeneca CEO Pascal Soriot is considering moving the company's stock market listing to the U.S., the Times reported on Tuesday, citing multiple sources. Soriot has privately expressed a ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

AstraZeneca CEO discusses leaving London for US and Japan facing new, bigger tariff - Stock markets updates and business news from Wednesday ...

AstraZeneca chief executive Pascal Soriot is considering moving the company's stock exchange listing from the UK to the US – ...

American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a ...

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

CEO Pascal Soriot has not hidden his annoyance at taxes and regulations the pharmaceutical firm have to navigate ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

--AstraZeneca's chief executive is considering moving its listing from London to the U.S. due to U.K. restrictions on medicines and pricing, The Times reports, citing unnamed sources. --Pascal ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...